Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Nov;62(Suppl 2):ii70–ii72. doi: 10.1136/ard.62.suppl_2.ii70

α4 Integrin blockade in inflammatory bowel disease

S Ghosh
PMCID: PMC1766747  PMID: 14532154

Full Text

The Full Text of this article is available as a PDF (212.1 KB).

Figure 1.

Figure 1

Open in a new tab

Lymphocyte trafficking to the intestine and key molecules involved.

Figure 2.

Figure 2

Open in a new tab

Rates of remission (CDAI<150) after different doses of natalizumab infusion compared with placebo. *Significant difference compared with placebo.6

Figure 3.

Figure 3

Open in a new tab

Rates of response (decrease in CDAI of at least 70 points from baseline) after different doses of natalizumab infusion compared with placebo. *Significant difference compared with placebo.6

Figure 4.

Figure 4

Open in a new tab

IBDQ scores in the four groups of patients.6

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binion D. G., West G. A., Volk E. E., Drazba J. A., Ziats N. P., Petras R. E., Fiocchi C. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet. 1998 Nov 28;352(9142):1742–1746. doi: 10.1016/S0140-6736(98)05050-8. [DOI] [PubMed] [Google Scholar]
  2. Ghosh Subrata, Goldin Eran, Gordon Fiona H., Malchow Helmut A., Rask-Madsen Jørgen, Rutgeerts Paul, Vyhnálek Petr, Zádorová Zdena, Palmer Tanya, Donoghue Stephen. Natalizumab for active Crohn's disease. N Engl J Med. 2003 Jan 2;348(1):24–32. doi: 10.1056/NEJMoa020732. [DOI] [PubMed] [Google Scholar]
  3. Gordon F. H., Hamilton M. I., Donoghue S., Greenlees C., Palmer T., Rowley-Jones D., Dhillon A. P., Amlot P. L., Pounder R. E. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002 Apr;16(4):699–705. doi: 10.1046/j.1365-2036.2002.01205.x. [DOI] [PubMed] [Google Scholar]
  4. Gordon F. H., Lai C. W., Hamilton M. I., Allison M. C., Srivastava E. D., Fouweather M. G., Donoghue S., Greenlees C., Subhani J., Amlot P. L. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001 Aug;121(2):268–274. doi: 10.1053/gast.2001.26260. [DOI] [PubMed] [Google Scholar]
  5. Hesterberg P. E., Winsor-Hines D., Briskin M. J., Soler-Ferran D., Merrill C., Mackay C. R., Newman W., Ringler D. J. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996 Nov;111(5):1373–1380. doi: 10.1053/gast.1996.v111.pm8898653. [DOI] [PubMed] [Google Scholar]
  6. Podolsky D. K., Lobb R., King N., Benjamin C. D., Pepinsky B., Sehgal P., deBeaumont M. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest. 1993 Jul;92(1):372–380. doi: 10.1172/JCI116575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Schreiber S., Nikolaus S., Malchow H., Kruis W., Lochs H., Raedler A., Hahn E. G., Krummenerl T., Steinmann G., German ICAM-1 Study Group Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology. 2001 May;120(6):1339–1346. doi: 10.1053/gast.2001.24015. [DOI] [PubMed] [Google Scholar]
  8. Yacyshyn B. R., Bowen-Yacyshyn M. B., Jewell L., Tami J. A., Bennett C. F., Kisner D. L., Shanahan W. R., Jr A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998 Jun;114(6):1133–1142. doi: 10.1016/s0016-5085(98)70418-4. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES